DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis

Journal of Cancer

Volumn 8, Issue 17, 2017, Pages

  Zhang, Chenzi ^a   Yu, Wenjun ^a   Wang, Lin ^a   Zhao, Mingna ^a   Guo, Qiaomei ^a   Lv, Shaogang ^a   Hu, Xiaomeng ^a   Lou, Jiatao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Diagnosis; DNA methylation; Lung cancer; RASSF1A; SHOX2

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CANCER CYTODIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; ELECTROCHEMILUMINESCENCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SHOX2 GENE; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA;

EID: 85030636399     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.21368     Document Type: Article

References (23)

1. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
3. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395-409.
4. Ren M, Wang C, Sheng D, et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. Ann Diagn Pathol. 2017; 27: 57-61.
5. Grunnet M and Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138-143.
6. Vizoso M, Puig M, Carmona FJ, et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis. 2015;36(12):1453-1463.
7. Stelzer Y, Shivalila CS, Soldner F, et al. Tracing dynamic changes of DNA methylation at single-cell resolution. Cell. 2015; 163(1):218-229.
8. Sandoval J, Peiro-Chova L, Pallardo FV, et al. Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities. Expert Rev Mol Diagn. 2013;13(5):457-471.
9. Sandoval J and Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 2012;22(1):50-55.
10. Wei H, Fang N, Guo L, et al. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2015;18(7): 443-450.
11. Darwiche K, Zarogoulidis P, Baehner K, et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol. 2013; 24(11): 2866-2870.
12. Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011;6(10):1632-1638.
13. Dietrich D, Jung M, Puetzer S, et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS One. 2013; 8(12): e84225.
14. Jung M, Putzer S, Gevensleben H, et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clin Epigenetics. 2016; 8:24.
15. Weiss G, Hasinger O, Esche S, et al. 31PD DNA methylation of SHOX2 and PTGER4 as a plasma-based tool to differentiate between patients with malignant and benign lung disease. Journal of Thoracic Oncology. 2016; 11(4):S68.
16. Weiss G, Schlegel A, Kottwitz D, et al. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol. 2017; 12(1):77-84.
17. Zhao W, Yu H, Han Z, et al. Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol. 2015; 8(8):9506-9511.
18. Song L, Yu H, and Li Y. Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay. Mol Diagn Ther. 2015; 19(3):159-167.
19. Shou F, Xu F, Li G, et al. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis. Onco Targets Ther. 2017;10:247-257.
20. Zhai X and Li SJ. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2014; 15(12):4925-4928.
21. Paska AV and Hudler P. Aberrant methylation patterns in cancer: a clinical view. Biochem Med (Zagreb). 2015;25(2):161-176.
22. Hu J, Qian GS, and Bai CX. Chinese consensus on early diagnosis of primary lung cancer (2014 version). Cancer. 2015;121 Suppl 17:3157-3164.
23. Wang H, Zhang X, Liu X, et al. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer. J Cancer Res Ther. 2016; 12(1):355-358.